Parnax Lab enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast closeFY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022FY21 and earlierAlpha Plus
0.50.50.41.34.3
FY21 and earlierEvery year the company has filed comes with Alpha Plus.
Reference items — trailing FY values
7.07.07.47.57.1
1.21.22.11.61.4
1.21.22.11.51.3
0.30.30.1−0.3−0.4
0.30.3−0.0−0.3−0.4
0.30.3−0.1−0.4—
0.00.00.10.1—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PARNAXLAB₹103.25

Parnax Lab Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDSGRLSHUKRAPHARSUNLOC
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Current
last close
- Cash, Equiv & ST Investments4.31.30.40.50.5
Reference Items — Trailing FY Values
Sales7.17.57.47.07.0
EBITDA1.41.62.11.21.2
EBIT1.31.52.11.21.2
Operating Cash Flow-0.4-0.30.10.30.3
Free Cash Flow-0.4-0.3-0.00.30.3
FCFF (free cash flow to the firm)—-0.4-0.10.30.3
Capital Expenditure—0.10.10.00.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.